These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36929498)

  • 1. Tofacitinib for new-onset adult patients with anti-melanoma differentiation-associated 5 gene antibody positive dermatomyositis.
    Wang Y; Luo J; Lv X; Li Y; An Q; Mo L; Hu N; Zhang J; Wang J; Tian J; Pu D; Hao Z; He L
    Clin Rheumatol; 2023 Jul; 42(7):1847-1853. PubMed ID: 36929498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients.
    Paik JJ; Casciola-Rosen L; Shin JY; Albayda J; Tiniakou E; Leung DG; Gutierrez-Alamillo L; Perin J; Florea L; Antonescu C; Leung SG; Purwin G; Koenig A; Christopher-Stine L
    Arthritis Rheumatol; 2021 May; 73(5):858-865. PubMed ID: 33258553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment with tofacitinib for anti-melanoma differentiation-associated gene 5 antibody-positive juvenile dermatomyositis: case reports and review of the literature.
    Yamazaki S; Shimizu M; Yakabe A; Inage E; Jimbo K; Suzuki M; Miyaoka F; Kaneko S; Irabu H; Shimbo A; Ohtomo Y; Mori M; Morio T; Shimizu T
    Immunol Med; 2024 Jun; 47(2):110-117. PubMed ID: 38557269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Tofacitinib in Anti-Melanoma Differentiation-Associated 5 Gene Antibody-Positive Dermatomyositis.
    Li S; Li S; Wang J; Zhang L; Duan J; Lu X; Zhang L; Wang G
    J Clin Rheumatol; 2023 Sep; 29(6):281-284. PubMed ID: 37496128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case report: Successful treatment of anti-MDA5-positive to negative dermatomyositis-associated interstitial lung disease with the JAK inhibitor tofacitinib.
    Jiang Z; Yao X; Tang F; Ma W
    Immun Inflamm Dis; 2023 Jun; 11(6):e897. PubMed ID: 37382261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis.
    Kurasawa K; Arai S; Namiki Y; Tanaka A; Takamura Y; Owada T; Arima M; Maezawa R
    Rheumatology (Oxford); 2018 Dec; 57(12):2114-2119. PubMed ID: 30060040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis.
    Ida T; Furuta S; Takayama A; Tamura J; Hayashi Y; Abe K; Kurihara S; Ishikawa J; Iwamoto T; Ikeda K; Suzuki K; Nakajima H
    RMD Open; 2023 Jan; 9(1):. PubMed ID: 36593080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of MDA5-positive dermatomyositis complicated by gangrenous cholecystitis with tofacitinib.
    Luo M; Chen L; He H; He F
    Eur J Med Res; 2022 May; 27(1):68. PubMed ID: 35570320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.
    Yoshida N; Okamoto M; Kaieda S; Fujimoto K; Ebata T; Tajiri M; Nakamura M; Tominaga M; Wakasugi D; Kawayama T; Kuwana M; Mimori T; Ida H; Hoshino T
    Respir Investig; 2017 Jan; 55(1):24-32. PubMed ID: 28012490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
    Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
    J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tofacitinib for recurrence of antimelanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis after remission: A case report.
    Ishikawa Y; Kasuya T; Fujiwara M; Kita Y
    Medicine (Baltimore); 2020 Sep; 99(37):e21943. PubMed ID: 32925726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of mortality for dermatomyositis patients positive with anti-melanoma differentiation-related gene 5 and optimal treatment.
    Liu L; Zhang Y; Shu X; Wang C; Guan W; Zhang X; Zhang L; Liu X; Wang L; Liu S; Li T
    Clin Exp Rheumatol; 2024 Feb; 42(2):246-252. PubMed ID: 37199165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab in the Treatment of Interstitial Lung Diseases Related to Anti-Melanoma Differentiation-Associated Gene 5 Dermatomyositis: A Systematic Review.
    He C; Li W; Xie Q; Yin G
    Front Immunol; 2021; 12():820163. PubMed ID: 35116041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review.
    Yu Z; Wang L; Quan M; Zhang T; Song H
    Rheumatology (Oxford); 2021 Apr; 60(4):1700-1707. PubMed ID: 33024992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib.
    Moghadam-Kia S; Charlton D; Aggarwal R; Oddis CV
    Rheumatology (Oxford); 2019 Jun; 58(6):1011-1015. PubMed ID: 30608616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Preliminary Study of Frequency and Clinical Relevance of Cytotoxic Peripheral CD4 and CD8 T Cells in Patients with Anti-MDA5 Positive Dermatomyositis.
    Jia F; Jiang S; Zhang J; Fu Q; Zhang X; Ye Y
    Rheumatol Immunol Res; 2022 Oct; 3(3):136-142. PubMed ID: 36788974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Janus kinase inhibition in induction treatment of anti-MDA5 juvenile dermatomyositis-associated rapidly progressive interstitial lung disease.
    Chan Ng PLP; Mopur A; Goh DYT; Ramamurthy MB; Lim MTC; Lim LK; Ooi PL; Ang EY
    Int J Rheum Dis; 2022 Feb; 25(2):228-231. PubMed ID: 34882988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis.
    Wu W; Guo L; Fu Y; Wang K; Zhang D; Xu W; Chen Z; Ye S
    Clin Rev Allergy Immunol; 2021 Apr; 60(2):293-304. PubMed ID: 33405101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful dose escalation of tofacitinib for refractory dermatomyositis and interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibodies.
    Ohmura SI; Yamabe T; Naniwa T
    Mod Rheumatol Case Rep; 2021 Jan; 5(1):76-81. PubMed ID: 32867615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy.
    Ge Y; Li S; Tian X; He L; Lu X; Wang G
    Clin Rheumatol; 2021 Jun; 40(6):2311-2317. PubMed ID: 33411136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.